Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 2.00
RTRX's Cash-to-Debt is ranked lower than
55% of the 827 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. RTRX: 2.00 )
Ranked among companies with meaningful Cash-to-Debt only.
RTRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.93 Max: No Debt
Current: 2
Equity-to-Asset 0.58
RTRX's Equity-to-Asset is ranked lower than
59% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. RTRX: 0.58 )
Ranked among companies with meaningful Equity-to-Asset only.
RTRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.16  Med: 0.36 Max: 0.63
Current: 0.58
-3.16
0.63
Debt-to-Equity 0.15
RTRX's Debt-to-Equity is ranked higher than
67% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. RTRX: 0.15 )
Ranked among companies with meaningful Debt-to-Equity only.
RTRX' s Debt-to-Equity Range Over the Past 10 Years
Min: -8.18  Med: 0.14 Max: 77.61
Current: 0.15
-8.18
77.61
Debt-to-EBITDA -0.83
RTRX's Debt-to-EBITDA is ranked lower than
99.99% of the 503 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. RTRX: -0.83 )
Ranked among companies with meaningful Debt-to-EBITDA only.
RTRX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.07  Med: -0.78 Max: 0.37
Current: -0.83
-1.07
0.37
Interest Coverage N/A
RTRX's Interest Coverage is ranked higher than
65% of the 641 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 106.84 vs. RTRX: N/A )
Ranked among companies with meaningful Interest Coverage only.
RTRX' s Interest Coverage Range Over the Past 10 Years
Min: 175.78  Med: No Debt Max: No Debt
Current: N/A
Beneish M-Score: -3.23
WACC vs ROIC
6.23%
-22.87%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -51.24
RTRX's Operating Margin % is ranked lower than
83% of the 781 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.94 vs. RTRX: -51.24 )
Ranked among companies with meaningful Operating Margin % only.
RTRX' s Operating Margin % Range Over the Past 10 Years
Min: -51.24  Med: 197.3 Max: 2105.03
Current: -51.24
-51.24
2105.03
Net Margin % -50.37
RTRX's Net Margin % is ranked lower than
83% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.12 vs. RTRX: -50.37 )
Ranked among companies with meaningful Net Margin % only.
RTRX' s Net Margin % Range Over the Past 10 Years
Min: -50.37  Med: 199.98 Max: 2059.37
Current: -50.37
-50.37
2059.37
ROE % -22.94
RTRX's ROE % is ranked lower than
80% of the 803 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.08 vs. RTRX: -22.94 )
Ranked among companies with meaningful ROE % only.
RTRX' s ROE % Range Over the Past 10 Years
Min: -22.94  Med: 36.75 Max: 89.25
Current: -22.94
-22.94
89.25
ROA % -13.42
RTRX's ROA % is ranked lower than
79% of the 831 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. RTRX: -13.42 )
Ranked among companies with meaningful ROA % only.
RTRX' s ROA % Range Over the Past 10 Years
Min: -575  Med: -240.01 Max: 36.2
Current: -13.42
-575
36.2
3-Year EBITDA Growth Rate -23.50
RTRX's 3-Year EBITDA Growth Rate is ranked lower than
91% of the 656 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.20 vs. RTRX: -23.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RTRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -23.5
Current: -23.5
3-Year EPS without NRI Growth Rate -19.10
RTRX's 3-Year EPS without NRI Growth Rate is ranked lower than
82% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.50 vs. RTRX: -19.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RTRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -19.1  Med: 76.5 Max: 172.1
Current: -19.1
-19.1
172.1
GuruFocus has detected 2 Warning Signs with Retrophin Inc RTRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RTRX's 30-Y Financials

Financials (Next Earnings Date: 2017-11-03)


Revenue & Net Income
Equity & Asset
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

RTRX Guru Trades in Q3 2016

Lee Ainslie 148,661 sh (New)
Paul Tudor Jones 66,213 sh (+74.40%)
Steven Cohen 150,800 sh (-13.73%)
» More
Q4 2016

RTRX Guru Trades in Q4 2016

Jim Simons 41,300 sh (New)
John Paulson 55,000 sh (New)
Steven Cohen 412,735 sh (+173.70%)
Lee Ainslie Sold Out
Paul Tudor Jones 51,666 sh (-21.97%)
» More
Q1 2017

RTRX Guru Trades in Q1 2017

Jim Simons 364,800 sh (+783.29%)
Steven Cohen 964,800 sh (+133.76%)
Paul Tudor Jones 61,733 sh (+19.48%)
John Paulson Sold Out
» More
Q2 2017

RTRX Guru Trades in Q2 2017

Steven Cohen 973,500 sh (+0.90%)
Jim Simons Sold Out
Paul Tudor Jones 38,231 sh (-38.07%)
» More
» Details

Insider Trades

Latest Guru Trades with RTRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2017-03-31 Sold Out 0.01%$17.39 - $21.59 $ 24.3024%0
John Paulson 2016-12-31 New Buy0.01%$17.62 - $23.12 $ 24.3019%55,000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325411    SIC: 2834
Compare:BKK:MEGA, SHSE:600129, SZSE:002198, XKRX:069620, SHSE:600713, SZSE:002393, LSE:VEC, TSE:4552, TSE:4559, SZSE:000788, SHSE:600488, SZSE:300357, SZSE:000605, SHSE:600285, SZSE:000756, SZSE:300006, TSE:4541, BOM:532300, SZSE:002433, IST:ECILC » details
Traded in other countries:17R.Germany,
Headquarter Location:USA
Retrophin Inc is a pharmaceutical company based in the United States. Its drug candidates are targeted at serious rare diseases such as gallstones and bile acid synthesis disorders.

Retrophin Inc serves in the healthcare sector based in the United States. As a pharmaceutical products manufacturer, it develops drugs to treat serious and rare diseases. Its suite of drug candidates includes Chenodal, to combat gallstones; Cholbam, which is approved for the treatment of bile acid synthesis disorders and Thiola, which addresses kidney stone formation.

Ratios

vs
industry
vs
history
PB Ratio 3.15
RTRX's PB Ratio is ranked lower than
55% of the 798 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.86 vs. RTRX: 3.15 )
Ranked among companies with meaningful PB Ratio only.
RTRX' s PB Ratio Range Over the Past 10 Years
Min: 1.43  Med: 2.46 Max: 8.33
Current: 3.15
1.43
8.33
PS Ratio 6.97
RTRX's PS Ratio is ranked lower than
75% of the 756 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.79 vs. RTRX: 6.97 )
Ranked among companies with meaningful PS Ratio only.
RTRX' s PS Ratio Range Over the Past 10 Years
Min: 1.89  Med: 9.84 Max: 76.25
Current: 6.97
1.89
76.25
Price-to-Operating-Cash-Flow 639.45
RTRX's Price-to-Operating-Cash-Flow is ranked lower than
99% of the 290 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.64 vs. RTRX: 639.45 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RTRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 149.05  Med: 505.26 Max: 2334.44
Current: 639.45
149.05
2334.44
EV-to-EBIT -12.48
RTRX's EV-to-EBIT is ranked lower than
99.99% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.28 vs. RTRX: -12.48 )
Ranked among companies with meaningful EV-to-EBIT only.
RTRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.3  Med: -4.1 Max: 12.6
Current: -12.48
-24.3
12.6
EV-to-EBITDA -16.37
RTRX's EV-to-EBITDA is ranked lower than
99.99% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.61 vs. RTRX: -16.37 )
Ranked among companies with meaningful EV-to-EBITDA only.
RTRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -29.8  Med: -4.1 Max: 11.2
Current: -16.37
-29.8
11.2
EV-to-Revenue 6.41
RTRX's EV-to-Revenue is ranked lower than
72% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.07 vs. RTRX: 6.41 )
Ranked among companies with meaningful EV-to-Revenue only.
RTRX' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.8  Med: 10.1 Max: 82
Current: 6.41
1.8
82

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -27.20
RTRX's 3-Year Average Share Buyback Ratio is ranked lower than
86% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. RTRX: -27.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RTRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -592.1  Med: -524.4 Max: -27.2
Current: -27.2
-592.1
-27.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 8.13
RTRX's Price-to-Tangible-Book is ranked lower than
80% of the 735 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. RTRX: 8.13 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RTRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.16  Med: 5.75 Max: 8.34
Current: 8.13
3.16
8.34
Price-to-Intrinsic-Value-Projected-FCF 11.85
RTRX's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
87% of the 306 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.32 vs. RTRX: 11.85 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
RTRX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 4.41  Med: 7.24 Max: 12.17
Current: 11.85
4.41
12.17
Price-to-Median-PS-Value 0.71
RTRX's Price-to-Median-PS-Value is ranked higher than
81% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.04 vs. RTRX: 0.71 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RTRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.2  Med: 0.56 Max: 2.13
Current: 0.71
0.2
2.13
Earnings Yield (Greenblatt) % -7.99
RTRX's Earnings Yield (Greenblatt) % is ranked lower than
82% of the 834 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.23 vs. RTRX: -7.99 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RTRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -65.6  Med: -10 Max: 22.6
Current: -7.99
-65.6
22.6

More Statistics

Revenue (TTM) (Mil) $139.05
EPS (TTM) $ -1.88
Beta0.69
Short Percentage of Float11.25%
52-Week Range $15.55 - 25.44
Shares Outstanding (Mil)38.39

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}